Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection

Virology

Volumn 390, Issue 2, 2009, Pages 348-355

  Bunnik, Evelien M ^a   van Gils, Marit J ^a   Lobbrecht, Marilie S D ^a   Pisas, Linaida ^a   van Nuenen, Ad C ^a   Schuitemaker, Hanneke ^a  

^a SANQUIN RESEARCH   (Netherlands)

Author keywords

Broadly neutralizing antibodies; HIV 1; Resistance mutations

Indexed keywords

AMINO ACID; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 2G12; MONOCLONAL ANTIBODY 4E10; MONOCLONAL ANTIBODY B12; NEUTRALIZING ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; VIRUS ISOLATION; VIRUS MUTATION; VIRUS NEUTRALIZATION; VIRUS RESISTANCE;

DNA, VIRAL; EPITOPES; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN G; MALE; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; NEUTRALIZATION TESTS; PROVIRUSES; SEQUENCE ANALYSIS, DNA;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 67650080603     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.05.028     Document Type: Article

References (46)

1. Beaumont T., van Nuenen A., Broersen S., Blattner W.A., Lukashov V.V., and Schuitemaker H. Reversal of HIV-1 IIIB towards a neutralization resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course. J. Virol. 75 (2001) 2246-2252
2. Beaumont T., Quakkelaar E., van Nuenen A., Pantophlet R., and Schuitemaker H. Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker. J. Virol. 78 (2004) 5651-5657
3. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., Stiegler G., Kunert R., Zolla-Pazner S., Katinger H., Petropoulos C.J., and Burton D.R. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78 (2004) 13232-13252
4. Binley J.M., Lybarger E.A., Crooks E.T., Seaman M.S., Gray E., Davis K.L., Decker J.M., Wycuff D., Harris L., Hawkins N., Wood B., Nathe C., Richman D., Tomaras G.D., Bibollet-Ruche F., Robinson J.E., Morris L., Shaw G.M., Montefiori D.C., and Mascola J.R. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 82 (2008) 11651-11668
5. Boom R., Sol C.J.A., Salimans M.M.M., Jansen C.L., Wertheim-van Dillen P.M.E., and Van der Noordaa J. A rapid and simple method for purification of nucleic acids. J. Clin. Microbiol. 28 (1991) 495-503
6. Bunnik E.M., Pisas L., van Nuenen A.C., and Schuitemaker H. Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J. Virol. 82 (2008) 7932-7941
7. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W.H., Sawyer L.S.W., Hendry R.M., Dunlop N., Nara P.L., Lamacchia M., Garratty E.M., Stiehm E.R., Bryson Y.J., Cao Y., Moore J.P., Ho D.D., and Barbas III C.F. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266 (1994) 1024-1027
8. Cardoso R.M., Zwick M.B., Stanfield R.L., Kunert R., Binley J.M., Katinger H., Burton D.R., and Wilson I.A. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22 (2005) 163-173
9. Chohan B., Lang D., Sagar M., Korber B., Lavreys L., Richardson B., and Overbaugh J. Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J. Virol. 79 (2005) 6528-6531
10. Derdeyn C.A., Decker J.M., Bibollet-Ruche F., Mokili J.L., Muldoon M., Denham S.A., Heil M.L., Kasolo F., Musonda R., Hahn B.H., Shaw G.M., Korber B.T., Allen S., and Hunter E. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303 (2004) 2019-2022
11. Dhillon A.K., Donners H., Pantophlet R., Johnson W.E., Decker J.M., Shaw G.M., Lee F.H., Richman D.D., Doms R.W., Vanham G., and Burton D.R. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J. Virol.. 81 (2007) 6548-6562
12. Duenas-Decamp M.J., Peters P., Burton D., and Clapham P.R. Natural resistance of human immunodeficiency virus type 1 to the CD4bs antibody b12 conferred by a glycan and an arginine residue close to the CD4 binding loop. J. Virol. 82 (2008) 5807-5814
13. Frost S.D., Liu Y., Pond S.L., Chappey C., Wrin T., Petropoulos C.J., Little S.J., and Richman D.D. Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J. Virol. 79 (2005) 6523-6527
14. Hall T.A. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl. Acids. Symp. Ser. 41 (1999) 95-98
15. Keele B.F., Giorgi E.E., Salazar-Gonzalez J.F., Decker J.M., Pham K.T., Salazar M.G., Sun c., Grayson T., Wang S., Li H., Wei X., Jiang C., Kirchherr J.L., Gao F., Anderson J.A., Ping L.H., Swanstrom R., Tomaras G.D., Blattner W.A., Goepfert P.A., Kilby J.M., Saag M.S., Delwart E.L., Busch M.P., Cohen M.S., Montefiori D.C., Haynes B.F., Gaschen B., Athreya G.S., Lee H.Y., Wood N., Seoighe C., Perelson A.S., Bhattacharya T., Korber B.T., Hahn B.H., and Shaw G.M. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 7552-7557
16. Koning F.A., Kwa D., Boeser-Nunnink B., Dekker J., Vingerhoed J., Hiemstra H., and Schuitemaker H. Decreasing sensitivity to RANTES neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection. J. Infect. Dis. 188 (2003) 864-872
17. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., Voss G., Goepfert P., Gilbert P., Greene K.M., Bilska M., Kothe D.L., Salazar-Gonzalez J.F., Wei X., Decker J.M., Hahn B.H., and Montefiori D.C. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79 (2005) 10108-10125
18. Li M., Salazar-Gonzalez J.F., Derdeyn C.A., Morris L., Williamson C., Robinson J.E., Decker J.M., Li Y., Salazar M.G., Polonis V.R., Mlisana K., Karim S.A., Hong K., Greene K.M., Bilska M., Zhou J., Allen S., Chomba E., Mulenga J., Vwalika C., Gao F., Zhang M., Korber B.T., Hunter E., Hahn B.H., and Montefiori D.C. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J. Virol. 80 (2006) 11776-11790
19. Li Y., Svehla K., Louder M.K., Wycuff D., Phogat S., Tang M., Migueles S.A., Wu X., Phogat A., Shaw G.M., Connors M., Hoxie J., Mascola J.R., and Wyatt R. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J. Virol. 83 (2009) 1045-1059
20. Manrique A., Rusert P., Joos B., Fischer M., Kuster H., Leemann C., Niederost B., Weber R., Stiegler G., Katinger H., Gunthard H.F., and Trkola A. In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J. Virol. 81 (2007) 8793-8808
21. Mo H., Stamatatos L., Ip J.E., Barbas C.F., Parren P.W.H.I., Burton D.R., Moore J.P., and Ho D.D. Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. J. Virol. 71 (1997) 6869-6874
22. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., Ruker F., and Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67 (1993) 6642-6647
23. Nakowitsch S., Quendler H., Fekete H., Kunert R., Katinger H., and Stiegler G. HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies. AIDS 19 (2005) 1957-1966
24. Ofek G., Tang M., Sambor A., Katinger H., Mascola J.R., Wyatt R., and Kwong P.D. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 78 (2004) 10724-10737
25. Pantophlet R., Ollman Saphire E., Poignard P., Parren P.W.H.I., Wilson I.A., and Burton D.R. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus Type 1 gp120. J. Virol. 77 (2002) 642-658
26. Quakkelaar E.D., van Alphen F.P., Boeser-Nunnink B.D., van Nuenen A.C., Pantophlet R., and Schuitemaker H. Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies. J. Virol. 81 (2007) 8533-8542
27. Repits J., Oberg M., Esbjornsson J., Medstrand P., Karlsson A., Albert J., Fenyo E.M., and Jansson M. Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. J. Gen. Virol. 86 (2005) 2859-2869
28. Richman D.D., Wrin T., Little S.J., and Petropoulos C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 4144-4149
29. Rusert P., Kuster H., Joos B., Misselwitz B., Gujer C., Leemann C., Fischer M., Stiegler G., Katinger H., Olson W.C., Weber R., Aceto L., Gunthard H.F., and Trkola A. Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. J. Virol. 79 (2005) 8454-8469
30. Sagar M., Wu X., Lee S., and Overbaugh J. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J. Virol. 80 (2006) 9586-9598
31. Sanders R.W., Venturi M., Schiffner L., Kalyanaraman R., Katinger H., Lloyd K.O., Kwong P.D., and Moore J.P. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 76 (2002) 7293-7305
32. Saphire E.O., Parren P.W., Pantophlet R., Zwick M.B., Morris G.M., Rudd P.M., Dwek R.A., Stanfield R.L., Burton D.R., and Wilson I.A. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 293 (2001) 1155-1159
33. Sather D.N., Armann J., Ching L.K., Mavrantoni A., Sellhorn G., Caldwell Z., Yu X., Wood B., Self S., Kalams S., and Stamatatos L. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83 (2009) 757-769
34. Scanlan C.N., Pantophlet R., Wormald M.R., Ollman Saphire E., Stanfield R., Wilson I.A., Katinger H., Dwek R.A., Rudd P.M., and Burton D.R. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alfa1 → 2 mannose residues on the outer face of gp120. J. Virol. 76 (2002) 7306-7321
35. Scheid J.F., Mouquet H., Feldhahn N., Seaman M.S., Velinzon K., Pietzsch J., Ott R.G., Anthony R.M., Zebroski H., Hurley A., Phogat A., Chakrabarti B., Li Y., Connors M., Pereyra F., Walker B.D., Wardemann H., Ho D., Wyatt R.T., Mascola J.R., Ravetch J.V., and Nussenzweig M.C. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458 (2009) 636-640
36. Schuitemaker H., Koot M., Kootstra N.A., Dercksen M.W., De Goede R.E.Y., Van Steenwijk R.P., Lange J.M.A., Eeftink Schattenkerk J.K.M., Miedema F., and Tersmette M. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus populations. J. Virol. 66 (1992) 1354-1360
37. Shen X., Parks R.J., Montefiori D.C., Kirchherr J.L., Keele B.F., Decker J.M., Blattner W.A., Gao F., Weinhold K.J., Hicks C.B., Greenberg M.L., Hahn B.H., Shaw G.M., Haynes B.F., and Tomaras G.D. In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J. Virol. 83 (2009) 3617-3625
38. Stiegler G., Kunert R., Purtscher M., Wolbank S., Voglauer R., Steindl F., and Katinger H. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 17 (2001) 1757-1765
39. Tersmette M., Winkel I.N., Groenink M., Gruters R.A., Spence P., Saman E., van der Groen G., Miedema F., and Huisman J.G. Detection and subtyping of HIV-1 isolates with a panel of characterized monoclonal antibodies to HIV-p24 gag. Virology 171 (1989) 149-155
40. Trkola A., Pomales A.B., Yuan H., Korber B., Maddon P.J., Allaway G.P., Katinger H., Barbas III C.F., Burton D.R., Ho D.D., and Moore J.P. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69 (1995) 6609-6617
41. Van 't Wout A.B., Schuitemaker H., and Kootstra N.A. Isolation and propagation of HIV-1 on peripheral blood mononuclear cells. Nat. Protoc. 3 (2008) 363-370
42. Verani A., Scarlatti G., Comar M., Tresoldi E., Polo S., Giacca M., Lusso P., Siccardi A.G., and Vercelli D. C-C chemokines released by lipopolysaccharide (LPS)-stimulated human macrophages suppress HIV-1 infection in both macrophages and T cells. J. Exp. Med. 5 (1997) 805-816
43. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., Hahn B.H., Kwong P.D., and Shaw G.M. Antibody neutralization and escape by HIV-1. Nature 422 (2003) 307-312
44. Zhang M., Gaschen B., Blay W., Foley B., Haigwood N., Kuiken C., and Korber B. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 14 (2004) 1229-1246
45. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Ollman Saphire E., Binley J.M., Moore J.P., Stiegler G., Katinger H., Burton D.R., and Parren P.W.H.I. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75 (2001) 10892-10905
46. Zwick M.B., Jensen R., Church S., Wang M., Stiegler G., Kunert R., Katinger H., and Burton D.R. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J. Virol. 79 (2005) 1252-1261